# Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595

**Authors:** Nicola Sgherza, Olga Battisti, Paola Curci, Concetta Conticello, Salvatore Palmieri, Daniele Derudas, Candida Germano, Enrica Antonia Martino, Giuseppe Mele, Roberta Della Pepa, Francesca Fazio, Anna Mele, Bernardo Rossini, Giulia Palazzo, Daniela Roccotelli, Simona Rasola, Maria Teresa Petrucci, Domenico Pastore, Giuseppe Tarantini, Fabrizio Pane, Massimo Gentile, Francesco Di Raimondo, Emanuela Resta, Pellegrino Musto

PMC · DOI: 10.3390/ph18060858 · Pharmaceuticals · 2025-06-09

## Full-text entities

- **Diseases:** Multiple Myeloma (MESH:D009101)
- **Chemicals:** IsaKd (-), Carfilzomib (MESH:C524865), Dexamethasone (MESH:D003907), Lenalidomide (MESH:D000077269), Isatuximab (MESH:C000599209)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12196246/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12196246/full.md

---
Source: https://tomesphere.com/paper/PMC12196246